Karyopharm to Present Selinexor Data in Myelofibrosis and Multiple Myeloma at ASH 2026

Karyopharm Therapeutics Inc. announced that abstracts from two clinical trials evaluating selinexor in patients with myelofibrosis were selected for oral presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. Additionally, data from a clinical trial assessing selinexor in combination with other therapies for multiple myeloma will be presented as a poster.